This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AdVEGF121.10, AdVEGF121, Ad-GV-VEGF121
Description: BIOBYPASS is intended to induce new blood vessel formation (angiogenesis) in tissues with inadequate blood flow. Vascular endothelial growth factor (VEGF) is a natural protein needed for the body's normal process of growing new blood vessels. BIOBYPASS angiogen delivers the VEGF 121 gene to the heart so that new blood vessels are formed in the diseased ischemic tissue. The gene is carried to the site of disease by GenVec's proprietary adenovector.
GenVec has exclusively licensed the patent-protected VEGF 121 gene from Scios on a worldwide basis for all gene therapy applications.
GenVec and Pfizer
In July 2002, GenVec announced that Pfizer has elected to discontinue co-development of BioBypass with GenVec. As a result, Pfizer returns its development and commercialization rights in BioBypass to GenVec and will not share in any royalties from potential future sales.
GenVec and Cordis (JNJ)
In January 2004, GenVec announced that it has entered into a research collaboration with the Cordis Cardiology Division of Cordis Corporation, a Johnson & Johnson company.
GenVec and Cordis will collaborate on regulatory matters and share in the clinical trial costs. GenVec will supply BIOBYPASS and Cordis will provide the NOGASTAR and MYOSTAR mapping and injection catheters and training to the interventional cardiologists conducting the trial. GenVec will retain commercial rights to BIOBYPASS, while...See full deal structure in Biomedtracker
Partners: Cardinal Health Inc.
BioBypass Angiogen News
Additional information available to subscribers only: